<DOC>
<DOCNO>EP-0623347</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Use of bisphosphoric acid derivatives for the manufacture of a medicament to improvement bone repair
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P4300	A61K3166	A61K31675	A61P4300	A61K31675	A61K3166	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61K	A61P	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P43	A61K31	A61K31	A61P43	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The subject of the present invention is the use of bisphosphonic acid derivatives of formula (I): 
<
IMAGE
>
  in which:   - R1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a monoalkyl(C1-C4)amino, a dialkyl(C1-C4)amino; - R2 represents a halogen atom, a linear alkyl containing from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a monoalkyl(C1-C4)amino, a dialkyl(C1-C4)amino, a cycloalkyl(C3-C7)amino, or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridylmethyl, a 1-pyridyl-1-hydroxymethyl, an imidazolylmethyl or a thiomorpholin-4-yl; and the use of the salts thereof with pharmaceutically acceptable inorganic or organic acids, for the preparation of medicaments for promoting bone repair, in human or veterinary medicine.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SANOFI SYNTHELABO
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI-SYNTHELABO
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BARBIER ALAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
LACHERETZ FREDERIC
</INVENTOR-NAME>
<INVENTOR-NAME>
BARBIER, ALAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
LACHERETZ, FREDERIC
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Claims for the following Contracting States : AT, BE, CH, DK, ES, GR, IE, IT, LI LU, NL, PT, SE
Use of a bisphosphonic acid derivative of the formula


in which:

R
1
 is a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono-C
1
-C
4
-alkylamino,
a di-C
1
-C
4
-alkylamino; and
R
2
 is a halogen atom, a linear alkyl containing from 1 to 5 carbon atoms
which is unsubstituted or substituted by a group selected from a chlorine

atom, a hydroxyl, an amino, a mono-C
1
-C
4
-alkylamino, a di-C
1
-C
4
-alkylamino,
a C
3
-C
7
-cycloalkylamino, or R
2
 is a phenoxy, a phenyl, a thiol, a
phenylthio, a chlorophenylthio, a pyridyl, a pyridylmethyl, a 1-pyridyl-1-hydroxymethyl,

an imidazolylmethyl, a thiomorpholin-4-yl ;

and of its salts with pharmaceutically acceptable mineral or organic acids for
the preparation of drugs designed to promote bone repair; said drugs being

intended for oral administration and also containing sodium laurylsulfate.
Use according to claim 1 in which the drug contains from
0.001 mg to 400 mg of bisphosphonic acid derivative(s) of formula (I).
Use according to claim 1 or 2 in which the drug contains from 0.1
to 250 mg of bisphosphonic acid derivative(s) of formula (I).
Use according to any one of claims 1 to 3 of:

2-pyridin-2-ylethylidenebisphosphonic acid, having the international non-proprietary
name piridronic acid, and its sodium salts ;
dichloromethylenebisphosphonic acid, having the international non-proprietary
name clodronic acid, and its sodium salts;
3-amino-1-hydroxypropylidenebisphosphonic acid, having the international
non-proprietary name pamidronic acid, and its sodium salts ;
4-amino-1-hydroxybutylidenebisphosphonic acid, having the international
non-proprietary name alendronic acid, and its sodium salts ;
6-amino-1-hydroxyhexylidenebisphosphonic acid and its pharmaceutically
acceptable salts; 
phenoxymethylenebisphosphonic acid and its pharmaceutically acceptable
salts;
thiomorpholinomethylenebisphosphonic acid and its pharmaceutically
acceptable salts;
4-chlorophenylthiomethylenebisphosphonic acid, having the non-proprietary
name tiludronic acid, and its pharmaceutically acceptable salts,

especially the disodium salt;
1-hydroxy-2-(pyridin-3-yl)ethylidenebisphosphonic acid, having the
international non-proprietary name risedronic acid, and its sodium salts;
1-hydroxy-2-(imidazol-2-yl)ethyl-1,1-bisphosphonic acid and its
pharmaceutically acceptable salts;
(cycloheptylamino)methylenebisphosphonic acid and its pharmaceutically
acceptable salts; and
2-hydroxyethylidene-2-(pyridin-3-yl)-1,1-bisphosphonic acid and its sodium
salts.
Use of a bisphosphonic acid derivative, selected from etidronic
acid and its pharmaceutically acceptable salts and the disodium salt of the

tiludronic acid, for the preparation of drugs designed to promote bone
repair.
Use according to claim 5 in which the drug contains from 0.001
mg to 400 mg of bisphosphonic acid derivative(s) according to said claim 5.
Use according to claim 5 or 6 in which the drug contains from 0.1
to 250 mg of bisphosphonic acid derivative(s) according to said claim 5.
Use according to any one of claims 5 to 7 for the preparation of
drugs intended for transdermal administration.
Use according to any one of claims 5 to 7 for the preparation of
drugs intended for oral administration.
Use according to claim 9, for the preparation of tablets having
the following composition, for 450 mg:


- disodium salt of tiludronic acid corresponding to 200 mg of acid
240 mg
- sodium laurylsulfate
4.5 mg
- crosslinked sodium carboxymethyl cellulose
24 mg
- microcrystalline lactose
177 mg
- magnesium stearate
4.5 mg
Use according to claim 9, for the preparation of tablets having
the following composition, for 114.5 mg: 


- disodium salt of tiludronic acid corresponding to 50 mg of acid
60 mg
- sodium laurylsulfate
3 mg
- crosslinked sodium carboxymethyl cellulose
6 mg
- anhydrous lactose
44.25 mg
- magnesium stearate
1.25 mg
Claims for the following Contracting States : DE, FR, GB
Use of a bisphosphonic acid derivative of the formula


in which:

R
1
 is a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono-C
1
-C
4
-alkylamino,
a di-C
1
-C
4
-alkylamino; and
R
2
 is a halogen atom, a linear alkyl containing from 1 to 5 carbon atoms
which is unsubstituted or substituted by a group selected from a chlorine

atom, a hydroxyl, an amino, a mono-C
1
-C
4
-alkylamino, a di-C
1
-C
4
-alkylamino,
a C
3
-C
7
-cycloalkylamino, or R
2
 is a phenoxy, a phenyl, a thiol, a
phenylthio, a chlorophenylthio, a pyridyl, a pyridylmethyl, a 1-pyridyl-1-hydroxymethyl,

an imidazolylmethyl, a thiomorpholin-4-yl;

and of its salts with pharmaceutically acceptable mineral or organic acids for

the preparation of drugs designed to promote bone repair; said drugs being
intended for oral administration and also containing sodium laurylsulfate.
Use according to claim 1 in which the drug contains from
0.001 mg to 400 mg of bisphosphonic acid derivative(s) of formula (I).
Use according to claim 1 or 2 in which the drug contains from 0.1
to 250 mg of bisphosphonic acid derivative(s) of formula (I).
Use according to any one of claims 1 to 3 of:

2-pyridin-2-ylethylidenebisphosphonic acid, having the international non-proprietary
name piridronic acid, and its sodium salts ;
dichloromethylenebisphosphonic acid, having the international non-proprietary
name clodronic acid, and its sodium salts ;
3-amino-1-hydroxypropylidenebisphosphonic acid, having the international
non-proprietary name pamidronic acid, and its sodium salts;
4-amino-1-hydroxybutylidenebisphosphonic acid, having the international
non-proprietary name alendronic acid, and its sodium salts;
6-amino-1-hydroxyhexylidenebisphosphonic acid and its pharmaceutically
acceptable salts; 
phenoxymethylenebisphosphonic acid and its pharmaceutically acceptable
salts;
thiomorpholinomethylenebisphosphonic acid and its pharmaceutically
acceptable salts;
4-chlorophenylthiomethylenebisphosphonic acid, having the non-proprietary
name tiludronic acid, and its pharmaceutically acceptable salts,

especially the disodium salt;
1-hydroxy-2-(pyridin-3-yl)ethylidenebisphosphonic acid, having the
international non-proprietary name risedronic acid, and its sodium salts ;
1-hydroxy-2-(imidazol-2-yl)ethyl-1,1-bisphosphonic acid and its
pharmaceutically acceptable salts ;
(cycloheptylamino)methylenebisphosphonic acid and its pharmaceutically
acceptable salts; and
2-hydroxyethylidene-2-(pyridin-3-yl)-1,1-bisphosphonic acid and its sodium
salts.
Use according to any one of claims 1 to 4, for the preparation of
tablets having the following composition, for 450 mg:


- disodium salt of tiludronic acid corresponding to 200 mg of acid
240 mg
- sodium laurylsulfate
4.5 mg
- crosslinked sodium carboxymethyl cellulose
24 mg
- microcrystalline lactose
177 mg
- magnesium stearate
4.5 mg
Use according to any one of claims 1 to 4, for the preparation of
tablets having the following composition, for 114.5 mg:


- disodium salt of tiludronic acid corresponding to 50 mg of acid
60 mg
- sodium laurylsulfate
3 mg
- crosslinked sodium carboxymethyl cellulose
6 mg
- anhydrous lactose
44.25 mg
- magnesium stearate
1.25 mg
</CLAIMS>
</TEXT>
</DOC>
